Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ellen Sidransky

Showing results (21-30 of 166) with videos related to

Pageof 17
Sort By:
Expert Opinion on Pharmacotherapy|March 13, 2021
Current and emerging pharmacotherapy for Gaucher disease in pediatric populationsRichard Sam, Emory Ryan, Emily Daykin, et al.
Current Opinion in Neurology|June 13, 2019
GBA1-associated parkinsonism: new insights and therapeutic opportunitiesEmory Ryan, Gurpreet Seehra, Pankaj Sharma, et al.
Current Chemical Genomics|December 4, 2010
Fabry disease - current treatment and new drug developmentOmid Motabar, Ellen Sidransky, Ehud Goldin, et al.
Fetal and Pediatric Pathology|January 7, 2006
Perinatal lethal Gaucher disease: a distinct phenotype along the neuronopathic continuumMichael J Eblan, Ozlem Goker-Alpan, Ellen Sidransky
Molecular Genetics and Metabolism|November 7, 2006
Therapy for Gaucher disease: don't stop thinking about tomorrowEllen Sidransky, Mary E LaMarca, Edward I Ginns
Trends in Molecular Medicine|September 19, 2020
Pro-cathepsin D, Prosaposin, and Progranulin: Lysosomal Networks in ParkinsonismNahid Tayebi, Grisel Lopez, Jenny Do, et al.
Trends in Neurosciences|January 17, 2022
Lysosomal dysfunction in neurodegeneration: emerging concepts and methodsVinod Udayar, Yu Chen, Ellen Sidransky, et al.
Therapeutics and Clinical Risk Management|January 30, 2025
Obstacles to Early Diagnosis of Gaucher DiseaseSamantha Nishimura, Charis Ma, Ellen Sidransky, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Is Gauchian genotyping of <i>GBA1</i> variants reliable?Nahid Tayebi, Jens Lichtenberg, Ellen Hertz, et al.
Journal of Biomedicine & Biotechnology|October 19, 2006
Gaucher disease and the synucleinopathiesKathleen S Hruska, Ozlem Goker-Alpan, Ellen Sidransky
Pageof 17

Showing results (21-30 of 166) with videos related to

Sort By:
Pageof 17
Expert Opinion on Pharmacotherapy|March 13, 2021
Current and emerging pharmacotherapy for Gaucher disease in pediatric populationsRichard Sam, Emory Ryan, Emily Daykin, et al.
Current Opinion in Neurology|June 13, 2019
GBA1-associated parkinsonism: new insights and therapeutic opportunitiesEmory Ryan, Gurpreet Seehra, Pankaj Sharma, et al.
Current Chemical Genomics|December 4, 2010
Fabry disease - current treatment and new drug developmentOmid Motabar, Ellen Sidransky, Ehud Goldin, et al.
Fetal and Pediatric Pathology|January 7, 2006
Perinatal lethal Gaucher disease: a distinct phenotype along the neuronopathic continuumMichael J Eblan, Ozlem Goker-Alpan, Ellen Sidransky
Molecular Genetics and Metabolism|November 7, 2006
Therapy for Gaucher disease: don't stop thinking about tomorrowEllen Sidransky, Mary E LaMarca, Edward I Ginns
Trends in Molecular Medicine|September 19, 2020
Pro-cathepsin D, Prosaposin, and Progranulin: Lysosomal Networks in ParkinsonismNahid Tayebi, Grisel Lopez, Jenny Do, et al.
Trends in Neurosciences|January 17, 2022
Lysosomal dysfunction in neurodegeneration: emerging concepts and methodsVinod Udayar, Yu Chen, Ellen Sidransky, et al.
Therapeutics and Clinical Risk Management|January 30, 2025
Obstacles to Early Diagnosis of Gaucher DiseaseSamantha Nishimura, Charis Ma, Ellen Sidransky, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Is Gauchian genotyping of <i>GBA1</i> variants reliable?Nahid Tayebi, Jens Lichtenberg, Ellen Hertz, et al.
Journal of Biomedicine & Biotechnology|October 19, 2006
Gaucher disease and the synucleinopathiesKathleen S Hruska, Ozlem Goker-Alpan, Ellen Sidransky
Pageof 17